IA Trial Radar | ||
|---|---|---|
O estudo clínico NCT06997497 para Adenocarcinoma do Cólon, Adenocarcinoma retal está em recrutamento. Consulte a visualização em cartões do Radar de Estudos Clínicos e as ferramentas de descoberta de IA para ver todos os detalhes. Ou pergunte qualquer coisa aqui. | ||
Um estudo corresponde aos critérios do filtro
Visualização em cartões
Voltar à pesquisa
MerckA Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) Fase III 477 Terapia alvo
Os detalhes do estudo clínico estão disponíveis principalmente em inglês. No entanto, a IA Trial Radar pode ajudar! Basta clicar em 'Explicar o estudo' para visualizar e discutir as informações do estudo no idioma selecionado.
O estudo clínico NCT06997497 procura avaliar tratamento para Adenocarcinoma do Cólon, Adenocarcinoma retal. Este é um estudo intervencionista de Fase III. Seu status atual é: em recrutamento. O estudo começou em 16 de julho de 2025 e pretende incluir 477 participantes. Coordenado por Merck e deve ser concluído em 27 de outubro de 2030. Essas informações foram atualizadas no ClinicalTrials.gov em 30 de março de 2026.
Resumo
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C.
Standard (or usual) treatments for this type of colorectal cancer may include mFOLFOX6 with or without bevacizumab. Researchers want to learn if adding calderasib (the study medicine) and cetuximab to mFOLFOX6 can treat locally advanced or mCRC with th...
Mostrar maisDescrição detalhada
This study will have 2 parts.
Título oficial
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)
Condições médicas
Adenocarcinoma do CólonAdenocarcinoma retalOutros IDs do estudo
- 1084-012
- MK-1084-012 (Outro identificador) (MSD)
- KANDLELIT-012 (Outro identificador) (MSD)
- 2024-517232-22-00 (Identificador de registro) (EU CT)
- U1111-1311-8311 (Identificador de registro) (UTN)
- jRCT2031250265 (Identificador de registro) (Japan Registry of Clinical Trials (jRCT))
Número NCT
Data de início (real)
2025-07-16
Última atualização postada
2026-03-30
Data de conclusão (estimada)
2030-10-27
Inscrição (estimada)
477
Tipo de estudo
Intervencionista
FASE
Fase III
Status
Em recrutamento
Propósito principal
Tratamento
Alocação do design
Randomizado
Modelo de intervenção
Paralelo
Cegamento (Mascaramento)
Cego simples
Braços / Intervenções
| Grupo de participantes/Braço | Intervenção/Tratamento |
|---|---|
ExperimentalCalderasib + Cetuximab + mFOLFOX6 Participants will receive calderasib orally, cetuximab per label every 2 weeks (Q2W), and mFOLFOX6 chemotherapy: oxaliplatin per label every 2 weeks (Q2W), leucovorin or levofolinate calcium per label Q2W, and 5-fluorouracil (5-FU) per label Q2W. Treatment will continue until criteria for discontinuation is met. | Calderasib Oral tablet Oxaliplatin Per label Leucovorin/levofolinate calcium Per label 5-Fluorouracil Per label Cetuximab Per label |
Comparador ativomFOLFOX6 Participants will receive mFOLFOX6 chemotherapy: oxaliplatin per label Q2W, leucovorin or levofolinate calcium per label Q2W, and 5-fluorouracil (5-FU) per label Q2W. Participants may also receive bevacizumab or bevacizumab biosimilar Q2W at the investigator's discretion. Treatment will continue until criteria for discontinuation is met. | Oxaliplatin Per label Leucovorin/levofolinate calcium Per label 5-Fluorouracil Per label Bevacizumab Per label Bevacizumab biosimilar Per label |
Desfecho primário
Desfecho secundário
| Medida de desfecho | Descrição da medida | Prazo |
|---|---|---|
Number of Participants Experiencing Dose-Limiting Toxicity (DLT) | A DLT is defined as the occurrence of protocol-specified toxicities if assessed by the investigator to be possibly, probably, or definitely related to study intervention administration. | Up to approximately 28 days |
Part 1: Number of Participants Who Experience an Adverse Event (AE) | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. | Up to approximately 44 months |
Part 1: Number of Participants Who Discontinue Study Treatment Due to an AE | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. | Up to approximately 44 months |
Progression Free Survival (PFS) | PFS is defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first. | Up to approximately 44 months |
| Medida de desfecho | Descrição da medida | Prazo |
|---|---|---|
Objective Response Rate (ORR) | ORR is defined as a confirmed complete response (CR: the disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR). The percentage of participants who experience CR or PR as assessed by BICR will be presented. | Up to approximately 3 years |
Overall Survival (OS) | OS is defined as the time from randomization to death due to any cause. | Up to approximately 5 years |
Duration of Response (DOR) | For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented. | Up to approximately 4 years |
Part 2: Number of Participants with an Adverse Event (AE) | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. | Up to approximately 5 years |
Part 2: Number of Participants who Discontinue Study Treatment Due to an AE | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. | Up to approximately 5 years |
Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score | The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to the questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and Quality of Life (QoL; "How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in GHS (EORTC QLQ-C30 Item 29) and QoL (EORTC QLQ-C30 Item 30) combined score will be presented. A higher score indicates a better outcome. | Baseline and up to approximately 5 years |
Change from Baseline in the EORTC-QLQ-C30 Physical Functioning (Items 1-5) Combined Score | The EORTC QLQ-C30 is a cancer specific health-related quality-of-life questionnaire. Participant responses to 5 questions about their physical functioning (Items 1-5) are scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate better physical functioning. The change from baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) combined score will be presented. | Baseline and up to approximately 5 years |
Change from Baseline in the EORTC-QLQ-C30 Role Functioning (Items 6 and 7) Combined Score | The EORTC QLQ-C30 is a cancer specific health-related quality-of-life questionnaire. The role functioning score is based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate better role functioning. The change from baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) combined score will be presented. | Baseline and up to approximately 5 years |
Change from Baseline in the EORTC-QLQ-C30 Appetite Loss (Item 13) Score | The EORTC QLQ-C30 is a cancer specific health-related quality-of life questionnaire, including a single-item scale score for appetite loss (QLQ-C30 Item 13). For this item, individual responses to the question "Have you lacked appetite?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-C30 appetite loss (Item 13) scale score will be presented. | Baseline and up to approximately 5 years |
Change from Baseline in the EORTC-Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score | The EORTC QLQ-CR29 is a health-related quality-of life questionnaire specific for colorectal cancer, including a single-item scale score for bloating (QLQ-CR29 Item 37). For this item, individual responses to the question "Did you have a bloated feeling in your abdomen?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-CR29 bloating (Item 37) scale score will be presented. | Baseline and up to approximately 5 years |
Time to First Deterioration (TTD) in EORTC QLQ-C30 Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score | The EORTC QLQ-C30 is a cancer specific health-related quality-of-life questionnaire. TTD is defined as the time from baseline to the first onset of a ≥10-point deterioration (decrease) from baseline in global health status (GHS) (EORTC QLQ-C30 Item 29) \& quality of life (QoL) combined score (EORTC QLQ-C30 Item 30). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in GHS and QoL combined score, will be presented. A longer TTD indicates a better outcome. | Baseline and up to approximately 5 years |
TTD in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score | The EORTC QLQ-C30 is a cancer specific health-related quality-of-life questionnaire. TTD is defined as the time from baseline to the first onset of a ≥10-point deterioration (decrease) from baseline in physical functioning score (EORTC QLQ-C30 Items 1-5). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in GHS and QoL combined score, will be presented. A longer TTD indicates a better outcome. | Baseline and up to approximately 5 years |
TTD in EORTC QLQ-C30 Role Functioning (Items 6 and 7) Score | The EORTC QLQ-C30 is a cancer specific health-related quality-of-life questionnaire. The role functioning score is based on participant responses to questions scored on a 4-point scale (1 = 'Not at All' to 4 = 'Very Much'). Higher scores indicate better role functioning. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in role functioning score, will be presented. A longer TTD indicates a better outcome. | Baseline and up to approximately 5 years |
TTD in EORTC QLQ-C30 Appetite Loss (Item 13) Score | The EORTC QLQ-C30 is a cancer specific health-related quality-of-life questionnaire. TTD is defined as the time from baseline to the first onset of a ≥10-point deterioration (decrease) from baseline in appetite loss score (EORTC QLQ-C30 Item 13). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in physical functioning score, will be presented. A longer TTD indicates a better outcome. | Baseline and up to approximately 5 years |
TTD in EORTC QLQ-CR29 Bloating (Item 37) Score | The EORTC QLQ-CR29 is a health-related quality-of life questionnaire specific for colorectal cancer, including a single-item scale score for bloating (QLQ-CR29 Item 37). TTD is defined as the time from baseline to the first onset of a ≥10-point deterioration (decrease) from baseline in bloating score (QLQ-CR29 Item 37). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in appetite loss score, will be presented. A longer TTD indicates a better outcome. | Baseline and up to approximately 5 years |
Assistente de participação
Critérios de elegibilidade
Idades elegíveis
Adulto, Idoso
Idade mínima
18 Years
Sexos elegíveis
Todos
The main inclusion criteria include but are not limited to the following:
- Has a histologically confirmed diagnosis of locally advanced unresectable or metastatic (unresectable Stage III or Stage IV as defined by American Joint Committee on Cancer \[AJCC\] eighth edition) colorectal adenocarcinoma
- Part 2 only: Has not received systemic anticancer therapy for locally advanced unresectable or metastatic colorectal cancer
- Tumor tissue demonstrates presence of a Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation
- Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)
- Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
The main exclusion criteria include but are not limited to the following:
- Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, chronic diarrhea)
- Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
- Has known dihydropyrimidine dehydrogenase (DPD) deficiency
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Has received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization
- Has 1 or more conditions that, in the opinion of the investigator, make the participant ineligible for treatment with bevacizumab
- Has known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis or leptomeningeal disease
- Has active infection requiring systemic therapy
- Has not adequately recovered from major surgery or have ongoing surgical complications
- Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
MerckContato central do estudo
Contato: Toll Free Number, 1-888-577-8839, [email protected]
137 Locais do estudo em 23 países
Pernambuco
Hospital de Câncer de Recife ( Site 0158), Recife, Pernambuco, 50040-000, Brazil
Study Coordinator, Contato, +558132178084
Em recrutamento
Rio Grande do Sul
Hospital de Caridade de Ijuí ( Site 0150), Ijuí, Rio Grande do Sul, 98700-000, Brazil
Study Coordinator, Contato, +55 55 981580022
Em recrutamento
Associação Hospitalar Beneficente São Vicente de Paulo ( Site 0153), Passo Fundo, Rio Grande do Sul, 99010-080, Brazil
Study Coordinator, Contato, +555433164000
Em recrutamento
Hospital Nossa Senhora da Conceição ( Site 0156), Porto Alegre, Rio Grande do Sul, 91350-200, Brazil
Study Coordinator, Contato, +5551993590437
Em recrutamento
Santa Catarina
CEPEN - Centro de Pesquisa e Ensino em Oncologia de Santa Catarina ( Site 0157), Florianópolis, Santa Catarina, 88020-210, Brazil
Study Coordinator, Contato, +554833804828
Em recrutamento
São Paulo
Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0155), Barretos, São Paulo, 14784-400, Brazil
Study Coordinator, Contato, +551733216600
Em recrutamento
Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0159), São José do Rio Preto, São Paulo, 15090-000, Brazil
Study Coordinator, Contato, +55 17 3201-5054
Em recrutamento
COE Ensino e Pesquisa ( Site 0151), São José dos Campos, São Paulo, 12242-660, Brazil
Study Coordinator, Contato, +5511960903468
Em recrutamento
Instituto do Cancer Arnaldo Vieira de Carvalho ( Site 0160), São Paulo, 01209-000, Brazil
Study Coordinator, Contato, +55 11 3225-0155
Em recrutamento
IBCC - Núcleo de Pesquisa e Ensino ( Site 0154), São Paulo, 04014-002, Brazil
Study Coordinator, Contato, +551134744222
Em recrutamento
California
Los Angeles Hematology Oncology Medical Group ( Site 0084), Los Angeles, California, 90017, United States
Study Coordinator, Contato, 213-533-9655
Em recrutamento
Florida
Orlando Health Cancer Institute ( Site 0065), Orlando, Florida, 32806, United States
Study Coordinator, Contato, 321-841-6780
Em recrutamento
Iowa
University of Iowa ( Site 0074), Iowa City, Iowa, 52242, United States
Study Coordinator, Contato, 319-356-4200
Em recrutamento
Kentucky
University of Kentucky ( Site 0055), Lexington, Kentucky, 40536, United States
Study Coordinator, Contato, 859-218-1758
Em recrutamento
Norton Cancer Institute, Audubon Hospital Campus ( Site 0054), Louisville, Kentucky, 40217, United States
Study Coordinator, Contato, 502-636-7845
Em recrutamento
Maryland
Greater Baltimore Medical Center ( Site 0068), Baltimore, Maryland, 21204, United States
Study Coordinator, Contato, 443-849-3051
Em recrutamento
Nebraska
University Of Nebraska Medical Center ( Site 0078), Omaha, Nebraska, 68198, United States
Study Coordinator, Contato, 402-559-4000
Em recrutamento
Nevada
Renown Regional Medical Center ( Site 0056), Reno, Nevada, 89502, United States
Study Coordinator, Contato, 775-982-4000
Em recrutamento
New Jersey
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0060), Hackensack, New Jersey, 07601, United States
Study Coordinator, Contato, 551-996-5855
Em recrutamento
Ohio
Miami Valley Hospital South ( Site 0075), Centerville, Ohio, 45459, United States
Study Coordinator, Contato, 937-438-2400
Em recrutamento
Utah
Community Cancer Trials of Utah ( Site 0086), Ogden, Utah, 84405, United States
Study Coordinator, Contato, 801-689-3909
Em recrutamento
Virginia
University of Virginia ( Site 0080), Charlottesville, Virginia, 22908, United States
Study Coordinator, Contato, 434-243-8237
Em recrutamento
Buenos Aires
Hospital Italiano de Buenos Aires ( Site 0102), Ciudad Autonoma de Buenos Aires, Buenos Aires, C1199ABB, Argentina
Study Coordinator, Contato, +5491155960279
Em recrutamento
Instituto Alexander Fleming ( Site 0101), Mar del Plata, Buenos Aires, C1426ANZ, Argentina
Study Coordinator, Contato, +5491166936669
Em recrutamento
Santa Fe Province
Fundacion Estudios Clinicos ( Site 0105), Rosario, Santa Fe Province, S2000CEJ, Argentina
Study Coordinator, Contato, +5493413168137
Em recrutamento
Hospital Privado Universitario de Córdoba ( Site 0108), Córdoba, X5016KEH, Argentina
Study Coordinator, Contato, +543514688846
Em recrutamento
Queensland
Sunshine Coast University Hospital ( Site 0451), Birtinya, Queensland, 4575, Australia
Study Coordinator, Contato, +61752020000
Em recrutamento
Victoria
Monash Health ( Site 0454), Clayton, Victoria, 3168, Australia
Study Coordinator, Contato, +61 03 8572-2941
Em recrutamento
Western Health-Sunshine & Footscray Hospitals ( Site 0450), St Albans, Victoria, 3021, Australia
Study Coordinator, Contato, +61383959167
Em recrutamento
New Brunswick
Moncton Hospital - Horizon Health Network ( Site 0011), Moncton, New Brunswick, E1C 6Z8, Canada
Study Coordinator, Contato, 5068575756
Em recrutamento
Ontario
Princess Margaret Cancer Centre ( Site 0001), Toronto, Ontario, M5G 2M9, Canada
Study Coordinator, Contato, 416-946-4559
Em recrutamento
Anhui
Anhui Provincial Cancer Hospital ( Site 0803), Hefei, Anhui, 230031, China
Study Coordinator, Contato, 0551-65327666
Em recrutamento
The Second Affiliated Hospital of Anhui Medical University ( Site 0813), Hefei, Anhui, 230601, China
Study Coordinator, Contato, 0551-63869536
Em recrutamento
Beijing Municipality
Peking Union Medical College Hospital ( Site 0824), Beijing, Beijing Municipality, 100730, China
Study Coordinator, Contato, 8613910113193
Em recrutamento
Peking University First Hospital(Daxing Area) ( Site 0838), Beijing, Beijing Municipality, 102627, China
Study Coordinator, Contato, 010-56957544
Em recrutamento
Chongqing Municipality
Chongqing University Cancer Hospital ( Site 0808), Chongqing, Chongqing Municipality, 400030, China
Study Coordinator, Contato, 13983841209
Em recrutamento
Chongqing University Three Gorges Hospital ( Site 0837), Wanzhou, Chongqing Municipality, 404199, China
Study Coordinator, Contato, 023-58103019
Em recrutamento
Fujian
Fujian Cancer Hospital ( Site 0807), Fuzhou, Fujian, 350014, China
Study Coordinator, Contato, +86 13509339525
Em recrutamento
The First Affiliated Hospital of Xiamen University ( Site 0806), Xiamen, Fujian, 361003, China
Study Coordinator, Contato, +86 13575559341
Em recrutamento
Guangdong
Sun Yat-Sen University Cancer Center ( Site 0800), Guangzhou, Guangdong, 510060, China
Study Coordinator, Contato, +86 02087343565
Em recrutamento
Southern Medical University Nanfang Hospital ( Site 0812), Guangzhou, Guangdong, 510515, China
Study Coordinator, Contato, +86 02062786845
Em recrutamento
The Sixth Affiliated Hospital of Sun Yat-sen University ( Site 0828), Guangzhou, Guangdong, 510655, China
Study Coordinator, Contato, 020-38254000
Em recrutamento
Guangxi
Guangxi Medical University Affiliated Tumor Hospital ( Site 0804), Nanning, Guangxi, 530200, China
Study Coordinator, Contato, +86 07715323175
Em recrutamento
Henan
Henan Cancer Hospital ( Site 0822), Zhengzhou, Henan, 450008, China
Study Coordinator, Contato, 037165587161
Em recrutamento
Hubei
Tongji Hospital Tongji Medical,Science & Technology ( Site 0839), Wuhan, Hubei, 430030, China
Study Coordinator, Contato, 027-83663940
Em recrutamento
Hubei Cancer Hospital ( Site 0814), Wuhan, Hubei, 430079, China
Study Coordinator, Contato, 027-87670500
Em recrutamento
Hunan
The Third Xiangya Hospital of Central South University ( Site 0834), Changsha, Hunan, 410013, China
Study Coordinator, Contato, 0731-88638888
Em recrutamento
Jiangsu
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 0825), Nanjing, Jiangsu, 210000, China
Study Coordinator, Contato, 025-83106666
Em recrutamento
Jiangxi
The First Affiliated Hospital of Nanchang University ( Site 0826), Nanchang, Jiangxi, 330200, China
Study Coordinator, Contato, 0791-88692748
Em recrutamento
Shandong
Jinan Central Hospital ( Site 0817), Jinan, Shandong, 250013, China
Study Coordinator, Contato, 0531-55739999
Em recrutamento
Shanghai Municipality
Fudan University Shanghai Cancer Center ( Site 0816), Shanghai, Shanghai Municipality, 200120, China
Study Coordinator, Contato, 021-64175590
Em recrutamento
Shanxi
First Affiliated Hospital of Shanxi Medical University ( Site 0843), Taiyuan, Shanxi, 030001, China
Study Coordinator, Contato, 0351-4639931
Em recrutamento
Sichuan
Sichuan Cancer hospital. ( Site 0831), Chengdu, Sichuan, 610213, China
Study Coordinator, Contato, 028-85420509
Em recrutamento
Yunnan
First Affiliated Hospital of Kunming Medical University ( Site 0845), Kunming, Yunnan, 650032, China
Study Coordinator, Contato, 087165324888
Em recrutamento
Zhejiang
The Second Affiliated Hospital of Zhejiang University School of Medicine ( Site 0801), Hangzhou, Zhejiang, 310017, China
Study Coordinator, Contato, 0571-87783777
Em recrutamento
Zhejiang Cancer Hospital ( Site 0821), Hangzhou, Zhejiang, 310022, China
Study Coordinator, Contato, 0571-88122222
Em recrutamento
The First Affiliated Hospital of Wenzhou Medical University ( Site 0840), Wenzhou, Zhejiang, 325000, China
Study Coordinator, Contato, +86057755579591
Em recrutamento
Cundinamarca
Hospital Universitario San Ignacio ( Site 0254), Bogota, Cundinamarca, 110231, Colombia
Study Coordinator, Contato, +573152931879
Em recrutamento
Departamento de Córdoba
IMAT S.A.S ( Site 0252), Montería, Departamento de Córdoba, 230002, Colombia
Study Coordinator, Contato, +576047862333
Em recrutamento
Risaralda Department
Oncologos Del Occidente ( Site 0255), Pereira, Risaralda Department, 660001, Colombia
Study Coordinator, Contato, +57 3187715522
Em recrutamento
Pirkanmaa
Tampere University Hospital ( Site 1001), Tampere, Pirkanmaa, 33520, Finland
Study Coordinator, Contato, +358503375000
Em recrutamento
Uusimaa
Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 1000), Helsinki, Uusimaa, 00290, Finland
Study Coordinator, Contato, +358504272703
Em recrutamento
Alpes-Maritimes
Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 1058), Nice, Alpes-Maritimes, 06202, France
Study Coordinator, Contato, +33492036021
Em recrutamento
Calvados
Centre François Baclesse ( Site 1061), Caen, Calvados, 14000, France
Study Coordinator, Contato, +33231455050
Em recrutamento
Lorraine
Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois ( Site 1053), Vandœuvre-lès-Nancy, Lorraine, 54511, France
Study Coordinator, Contato, +33772081634
Em recrutamento
Marne
Institut Jean Godinot ( Site 1054), Reims, Marne, 51100, France
Study Coordinator, Contato, +33326504246
Em recrutamento
Pays de la Loire Region
Institut de Cancérologie de l'Ouest ( Site 1062), Angers, Pays de la Loire Region, 49055, France
Study Coordinator, Contato, +33241352700
Em recrutamento
Seine-Maritime
CHU Charles Nicolle ( Site 1066), Rouen, Seine-Maritime, 76031, France
Study Coordinator, Contato, +33232888148
Em recrutamento
Vaucluse
Sainte Catherine Institut du Cancer Avignon Provence ( Site 1065), Avignon, Vaucluse, 84918, France
Study Coordinator, Contato, +33490276161
Em recrutamento
Katholisches Marienkrankenhaus gGmbH ( Site 1103), Hamburg, 22087, Germany
Study Coordinator, Contato, 00494025460
Em recrutamento
Prince of Wales Hospital. ( Site 0500), Hong Kong, Hong Kong
Study Coordinator, Contato, + 852 3505 2211
Em recrutamento
Queen Mary Hospital ( Site 0501), Hong Kong, Hong Kong
Study Coordinator, Contato, +852 2255 3838
Em recrutamento
Rambam Health Care Campus ( Site 1253), Haifa, 3109601, Israel
Study Coordinator, Contato, +97247776234
Em recrutamento
Hadassah Medical Center ( Site 1252), Jerusalem, 9112001, Israel
Study Coordinator, Contato, 02-6777111
Em recrutamento
Rabin Medical Center ( Site 1251), Petah Tikva, 4941492, Israel
Study Coordinator, Contato, 03-9377589
Em recrutamento
Sheba Medical Center ( Site 1254), Ramat Gan, 5265601, Israel
Study Coordinator, Contato, +97235303030
Em recrutamento
Cagliari
AOU Cagliari ( Site 1306), Monserrato, Cagliari, 09042, Italy
Study Coordinator, Contato, +39 07051096037
Em recrutamento
Ospedale San Raffaele. ( Site 1305), Milan, 20132, Italy
Study Coordinator, Contato, +39.0226435138
Em recrutamento
Azienda Ospedaliera Universitaria dell'Università "Luigi Van-UOC Oncoematologia ( Site 1302), Naples, 80131, Italy
Study Coordinator, Contato, 00390815666760
Em recrutamento
Istituto Oncologico Veneto IRCCS ( Site 1307), Padua, 35128, Italy
Study Coordinator, Contato, 390498215910
Em recrutamento
Azienda USL della Romagna ( Site 1303), Ravenna, 48100, Italy
Study Coordinator, Contato, 00390544285247
Em recrutamento
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma ( Site 1304), Verona, 37134, Italy
Study Coordinator, Contato, 00393200117982
Em recrutamento
Chiba
National Cancer Center Hospital East ( Site 0851), Kashiwa, Chiba, 277-8577, Japan
Study Coordinator, Contato, +81-4-7133-1111
Em recrutamento
Hokkaido
Teine Keijinkai Hospital ( Site 0864), Sapporo, Hokkaido, 006-8555, Japan
Study Coordinator, Contato, +81-11-681-8111
Em recrutamento
Kagawa-ken
Kagawa University Hospital ( Site 0861), Kita-gun, Kagawa-ken, 761-0793, Japan
Study Coordinator, Contato, +81-87-891-2345
Em recrutamento
Miyagi
Tohoku University Hospital ( Site 0853), Sendai, Miyagi, 980-8574, Japan
Study Coordinator, Contato, +81-22-717-7000
Em recrutamento
Osaka
Kindai University Hospital ( Site 0854), Sakai, Osaka, 590-0197, Japan
Study Coordinator, Contato, +81-72-366-0221
Em recrutamento
Saitama
Saitama Medical University International Medical Center ( Site 0860), Hidaka, Saitama, 350-1298, Japan
Study Coordinator, Contato, +81-42-984-4111
Em recrutamento
Tokyo
Nippon Medical School Hospital ( Site 0859), Bunkyo, Tokyo, 113-8603, Japan
Study Coordinator, Contato, +81-3-3822-2131
Em recrutamento
National Cancer Center Hospital ( Site 0850), Chūō, Tokyo, 104-0045, Japan
Study Coordinator, Contato, +81-3-3542-2511
Em recrutamento
Cancer Institute Hospital of JFCR ( Site 0863), Koto, Tokyo, 135-8550, Japan
Study Coordinator, Contato, +81-3-3520-0111
Em recrutamento
Kyushu University Hospital ( Site 0862), Fukuoka, 812-8582, Japan
Study Coordinator, Contato, +81-92-642-5774
Em recrutamento
Gelderland
Radboudumc ( Site 1354), Nijmegen, Gelderland, 6525 GA, Netherlands
Study Coordinator, Contato, +31 24 3610353
Em recrutamento
North Brabant
Amphia Ziekenhuis, locatie Breda Molengracht ( Site 1352), Breda, North Brabant, 4818 CK, Netherlands
Study Coordinator, Contato, +31 76 5951006
Em recrutamento
North Holland
Amsterdam UMC, locatie VUmc ( Site 1351), Amsterdam, North Holland, 1081 HV, Netherlands
Study Coordinator, Contato, +31204444321
Em recrutamento
Greater Poland Voivodeship
Wielkopolskie Centrum Onkologii im. Marii Skłodowskiej-Curie ( Site 1457), Poznan, Greater Poland Voivodeship, 61-866, Poland
Study Coordinator, Contato, +48943488930
Em recrutamento
Cluj
Institutul Oncologic Cluj ( Site 1502), Cluj-Napoca, Cluj, 400015, Romania
Study Coordinator, Contato, +40 264 598 362
Em recrutamento
SC Radiotherapy Center Cluj SRL-Oncologie Medicala ( Site 1501), Cluj-Napoca, Cluj, 407280, Romania
Study Coordinator, Contato, 021 9368
Em recrutamento
Dolj
Centrul de Oncologie Sfantul Nectarie-Medical ( Site 1500), Craiova, Dolj, 200746, Romania
Study Coordinator, Contato, +40 731 604 432
Em recrutamento
Fundeni Clinical Institute-Medical Oncology ( Site 1504), Bucharest, 022328, Romania
Study Coordinator, Contato, +4021 275 0500
Em recrutamento
Institutul Regional de Oncologie ( Site 1505), Iași, 700483, Romania
Study Coordinator, Contato, +40374278811
Em recrutamento
Central Singapore
National Cancer Centre Singapore ( Site 0650), Singapore, Central Singapore, 168583, Singapore
Study Coordinator, Contato, +6564368000
Em recrutamento
Kyonggi-do
National Cancer Center ( Site 0702), Goyang-si, Kyonggi-do, 10408, South Korea
Study Coordinator, Contato, +82319201737
Em recrutamento
Seoul National University Bundang Hospital ( Site 0705), Seongnam-si, Kyonggi-do, 13620, South Korea
Study Coordinator, Contato, +8215883369
Em recrutamento
The Catholic University of Korea St. Vincent s Hospital ( Site 0703), Suwon, Kyonggi-do, 16247, South Korea
Study Coordinator, Contato, 82-31-881-8893
Em recrutamento
Seoul
Samsung Medical Center ( Site 0708), Gangnam, Seoul, 06351, South Korea
Study Coordinator, Contato, +82234100297
Em recrutamento
Asan Medical Center ( Site 0707), Songpa-gu, Seoul, 05505, South Korea
Study Coordinator, Contato, 82-2-3010-3204
Em recrutamento
Taegu-Kwangyokshi
Kyungpook National University Chilgok Hospital ( Site 0701), Buk-Gu, Taegu-Kwangyokshi, 41404, South Korea
Study Coordinator, Contato, +82532003011
Em recrutamento
Seoul National University Hospital ( Site 0706), Seoul, 03080, South Korea
Study Coordinator, Contato, +82-2-1588-5700
Em recrutamento
Korea University Guro Hospital ( Site 0704), Seoul, 08308, South Korea
Study Coordinator, Contato, 82226263060
Em recrutamento
Barcelona
Institut Català d'Oncologia (ICO) - Badalona ( Site 1552), Badalona, Barcelona, 08916, Spain
Study Coordinator, Contato, 34 934 97 89 25
Em recrutamento
Cantabria
Hospital Universitario Marqués de Valdecilla ( Site 1551), Santander, Cantabria, 39008, Spain
Study Coordinator, Contato, +34 942202525
Em recrutamento
Las Palmas
Hospital Insular de Gran Canaria ( Site 1558), Las Palmas de Gran Canaria, Las Palmas, 35016, Spain
Study Coordinator, Contato, 34 928441738
Em recrutamento
Principality of Asturias
Hospital Universitario Central de Asturias ( Site 1550), Oviedo, Principality of Asturias, 33011, Spain
Study Coordinator, Contato, 34 985108000x36582
Em recrutamento
Hospital Universitari Vall d'Hebron ( Site 1553), Barcelona, 08035, Spain
Study Coordinator, Contato, +34 93 489 43 50
Em recrutamento
HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 1554), Madrid, 28007, Spain
Study Coordinator, Contato, +34914269325
Em recrutamento
Hospital Clinico San Carlos ( Site 1555), Madrid, 28040, Spain
Study Coordinator, Contato, 34913303000x484833
Em recrutamento
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 1556), Seville, 41013, Spain
Study Coordinator, Contato, +34 955 013 068
Em recrutamento
Instituto Valenciano de Oncologia - IVO ( Site 1557), Valencia, 46009, Spain
Study Coordinator, Contato, 34961114000
Em recrutamento
National Cheng Kung University Hospital ( Site 0754), Tainan, 704, Taiwan
Study Coordinator, Contato, +88662353535
Em recrutamento
National Taiwan University Hospital ( Site 0751), Taipei, 100, Taiwan
Study Coordinator, Contato, +886-2-23123456
Em recrutamento
Taipei Veterans General Hospital ( Site 0752), Taipei, 112, Taiwan
Study Coordinator, Contato, +886228712121
Em recrutamento
Chang Gung Memorial Hospital - Linkou Branch ( Site 0753), Taoyuan District, 333, Taiwan
Study Coordinator, Contato, +88633281200
Em recrutamento
Cherkasy Oblast
MNE "Clinical Center of Oncology, Hematology, Transplantology and Palliative Care of CRC" ( Site 1706), Cherkasy, Cherkasy Oblast, 18009, Ukraine
Study Coordinator, Contato, +380472319418
Em recrutamento
Chernivetska Oblast
RMNE "Bukovyna Clinical Oncology Center" ( Site 1709), Chernivtsi, Chernivetska Oblast, 58013, Ukraine
Study Coordinator, Contato, 0443344770
Em recrutamento
Ivano-Frankivsk Oblast
MNPE "Prykarpattia Clinical Oncology Center of Ivano-Frankivsk Regional Council" ( Site 1701), Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76018, Ukraine
Study Coordinator, Contato, +380966059053
Em recrutamento
Kirovohrad Oblast
CNE "Regional Clinical Oncology Center of the Kirovohrad Regional Council" ( Site 1702), Kropyvnytskyi, Kirovohrad Oblast, 25011, Ukraine
Study Coordinator, Contato, +380508427973
Em recrutamento
Lviv Oblast
MNPE LTMU Multidisc. Clin. Hosp. of Emerg. and Intens. Care ( Site 1708), Lviv, Lviv Oblast, 79059, Ukraine
Study Coordinator, Contato, +380977453295
Em recrutamento
Rivne Oblast
MNE "Central City Hospital" ( Site 1711), Rivne, Rivne Oblast, 33017, Ukraine
Study Coordinator, Contato, +380508266088
Em recrutamento
Volyn Oblast
ME "Volyn Regional Clinical Hospital" of the VRC ( Site 1712), Lutsk, Volyn Oblast, +380332773100, Ukraine
Study Coordinator, Contato, 380503782998
Em recrutamento
Zakarpattia Oblast
Uzhgorod Central City Clinical Hospital ( Site 1700), Uzhhorod, Zakarpattia Oblast, 88000, Ukraine
Study Coordinator, Contato, +380953274431
Em recrutamento
Medical Center "Universal Clinic "Oberig" of Limited Liability Company "Kapytal" ( Site 1704), Kyiv, 03057, Ukraine
Study Coordinator, Contato, +380669472333
Em recrutamento
SI "National Institute of Surgery and Transplantology named after O. O. Shalimov" ( Site 1713), Kyiv, 03126, Ukraine
Study Coordinator, Contato, +380956017249
Em recrutamento
LLC "MEDICAL CENTER DOBROBUT-CLINIC" ( Site 1703), Kyiv, 03151, Ukraine
Study Coordinator, Contato, +380671502987
Em recrutamento
London, City of
University College London Hospitals ( Site 1750), London, London, City of, NW1 2PG, United Kingdom
Study Coordinator, Contato, 020 3456 7890
Em recrutamento
Oxfordshire
Churchill Hospital ( Site 1756), Oxford, Oxfordshire, ox3 7le, United Kingdom
Study Coordinator, Contato, +4403003047777
Em recrutamento
The Christie NHS Foundation Trust ( Site 1755), Manchester, M20 4BX, United Kingdom
Study Coordinator, Contato, +441614468370
Em recrutamento